Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs.
Dogs were experimentally inoculated with Rickettsia rickettsii (canine origin) in order to compare the efficacies of azithromycin and trovafloxacin to that of the current antibiotic standard, doxycycline, for the treatment of Rocky Mountain spotted fever. Clinicopathologic parameters, isolation of rickettsiae in tissue culture, and PCR amplification of rickettsial DNA were used to evaluate the response to therapy or duration of illness (untreated infection control group) in the four groups. Concentrations of the three antibiotics in plasma and blood cells were measured by high-performance liquid chromatography. Doxycycline and trovafloxacin treatments resulted in more-rapid defervescence, whereas all three antibiotics caused rapid improvement in attitudinal scores, blood platelet numbers, and the albumin/total-protein ratio. Based upon detection of retinal vascular lesions by fluorescein angiography, trovafloxacin and doxycycline substantially decreased rickettsia-induced vascular injury to the eye, whereas the number of ocular lesions in the azithromycin group did not differ from that in the infection control group. As assessed by tissue culture isolation, doxycycline resulted in the earliest apparent clearance of viable circulating rickettsiae; however, rickettsial DNA could still be detected in the blood of some dogs from all four groups on day 21 postinfection, despite our inability to isolate viable rickettsiae at that point. As administered in this study, trovafloxacin was as efficacious as doxycycline but azithromycin proved less efficacious, possibly due to the short duration of administration.
Breitschwerdt
E B
EB
Department of Companion Animal, College of Veterinary Medicine, North Carolina State University, Raleigh 27606, USA. Ed_Breitschwerdt@ncsu.edu
Papich
M G
MG
Hegarty
B C
BC
Gilger
B
B
Hancock
S I
SI
Davidson
M G
MG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000097:blood / Q000627:therapeutic use*; D017963:Azithromycin / Q000097:blood / Q000627:therapeutic use*; D002199:Capillary Permeability / Q000187:drug effects; D004269:DNA, Bacterial / Q000032:analysis; D004285:Dogs; D004318:Doxycycline / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006168:Guinea Pigs; D008297:Male; D009287:Naphthyridines / Q000097:blood / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D012284:Rickettsia rickettsii / Q000187:drug effects / Q000302:isolation & purification; D012373:Rocky Mountain Spotted Fever / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D009287:Naphthyridines; D017963:Azithromycin; C080163:trovafloxacin; D004318:Doxycycline